Cancer patients can keep taking promising drug in Follow-Up study
NCT ID NCT06246643
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study is for people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study and are benefiting from it. They can continue taking the same dose to see how safe and tolerable it is over a longer period. The study involves about 13 participants and includes regular check-ups and blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID MALIGNANT TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
China Medical University Hospital
Taichung, 404327, Taiwan
-
Hopital Claude Huriez - Lille
Lille, Hauts-de-France, 59037, France
-
Hospital Infantil Universitario Nino Jesus | Oncologia Pediatrica
Madrid, 28009, Spain
-
Hôpital Beaujon - Clichy
Clichy, Île-de-France Region, 92110, France
-
Hôpital Paul Brousse - Villejuif
Villejuif, Île-de-France Region, 94800, France
-
Saitama Cancer Center
Kitaadachi-gun, Saitama, 362-0806, Japan
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 3080, South Korea
Conditions
Explore the condition pages connected to this study.